Company Page

Violet Therapeutics is a preclinical-stage biotechnology company co-founded in 2021 by Mass General Brigham Ventures and scientists from Brigham and Women's Hospital. The company leverages its proprietary CONNECT platform to map large-scale cell-to-cell interaction networks in the brain, identifying novel signaling pathways that drive neuroinflammation and neurodegeneration. Its lead program targets EphB3, a receptor tyrosine kinase mediating microglia-astrocyte signaling implicated in synaptic loss and cognitive decline across multiple neurodegenerative diseases including Alzheimer's.

Company Founded in 2021

Healthtech & Biotech